BeiGene, Ltd. (6160.HK)
| Previous Close | 99.400 |
| Open | 99.350 |
| Bid | 99.050 x 0 |
| Ask | 99.100 x 0 |
| Day's Range | 96.750 - 99.700 |
| 52 Week Range | 75.450 - 139.900 |
| Volume | |
| Avg. Volume | 1,313,662 |
| Market Cap | 139.712B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.530 |
| Earnings Date | Jul 31, 2024 - Aug 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 167.93 |
Business WireBeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
SAN MATEO, Calif., June 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session (Abstract S160). The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chronic
Business WireBeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
DUBAI, United Arab Emirates, June 13, 2024--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its presence and directly manage operations in the MENA region.
Simply Wall St.BeiGene, Ltd. (NASDAQ:BGNE) Shares Could Be 47% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for BeiGene is US$318 based on 2 Stage Free Cash Flow to Equity Current share...
